{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Label&page=8",
    "query": {
      "condition": "Open Label",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 17643,
    "total_pages": 1765,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Label&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Label&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T06:39:53.325Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02796937",
      "title": "Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 MP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "20 Years to 72 Years"
      },
      "enrollment_count": 290,
      "start_date": "2016-07",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796937"
    },
    {
      "nct_id": "NCT01192295",
      "title": "Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Oxycodone HCl controlled-release tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 155,
      "start_date": "2010-11",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2020-03-23",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01192295"
    },
    {
      "nct_id": "NCT00111319",
      "title": "VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-03-26",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00111319"
    },
    {
      "nct_id": "NCT06878365",
      "title": "A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Interferonopathies"
      ],
      "interventions": [
        {
          "name": "BI 3000202_low dose",
          "type": "DRUG"
        },
        {
          "name": "BI 3000202_high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 16,
      "start_date": "2025-07-29",
      "completion_date": "2026-12-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06878365"
    },
    {
      "nct_id": "NCT06588283",
      "title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Ixekizumab",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 281,
      "start_date": "2024-09-30",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 68,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06588283"
    },
    {
      "nct_id": "NCT03130556",
      "title": "A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Glasdegib",
          "type": "DRUG"
        },
        {
          "name": "High Fat, High Calorie Meal",
          "type": "OTHER"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-05-01",
      "completion_date": "2017-07-21",
      "has_results": false,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03130556"
    },
    {
      "nct_id": "NCT02452931",
      "title": "Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Precocious Puberty, Central"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate 45 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tolmar Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "2 Years to 9 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-08-31",
      "completion_date": "2018-09-05",
      "has_results": true,
      "last_update_posted_date": "2020-06-02",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 10,
      "location_summary": "San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452931"
    },
    {
      "nct_id": "NCT01083602",
      "title": "Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed and Bortezomib Refractory Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "panobinostat",
          "type": "DRUG"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2010-06",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2017-12-21",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Stanford, California • Tampa, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01083602"
    },
    {
      "nct_id": "NCT01102972",
      "title": "A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Reyataz + Norvir + Truvada",
          "type": "DRUG"
        },
        {
          "name": "Reyataz + Epzicom",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 297,
      "start_date": "2010-04",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 44,
      "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01102972"
    },
    {
      "nct_id": "NCT07426757",
      "title": "An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07994525",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2026-07-01",
      "completion_date": "2030-07-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-25T06:39:53.325Z",
      "location_count": 24,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • North Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07426757"
    }
  ]
}